rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Edwards Lifesciences Corporation

EW · NYSE

Health CareMedical DevicesJust started moving

EW stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 12 weeks. It is 1.4% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
12 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$49.0M
Officials’ trades on record
43

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$13.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

43 disclosed lines: House 33, Senate 7, executive 3; 20 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k11 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k10 Apr 2026filed 1 Jul 2026
Alan Armstrong Senate: U.S. Senate eFDSenatorbought$1k–$15k27 Mar 2026filed 21 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$500k–$1M10 Feb 2026filed 14 May 2026
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k19 Nov 2025filed 29 Dec 2025
Jefferson Shreve House: U.S. House ClerkIN06sold$50k–$100k12 May 2025filed 22 Jun 2025
Bruce Westerman House: U.S. House ClerkAR04sold$1k–$15k21 Apr 2025filed 12 May 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08bought$1k–$15k8 Apr 2025filed 8 May 2025
Jefferson Shreve House: U.S. House ClerkIN06bought$15k–$50k7 Apr 2025filed 8 May 2025
Bruce Westerman House: U.S. House ClerkAR04bought$1k–$15k3 Mar 2025filed 16 Apr 2025
Markwayne Mullin Senate: U.S. Senate eFDSenatorsold part ofjoint$15k–$50k20 Aug 2024filed 19 Sep 2024
Mike Kelly House: U.S. House ClerkPA16soldspouse$1k–$15k11 Apr 2024filed 14 Jun 2024

Insiders

Buy orders, 12 months0
Sale orders, 12 months43
Buyers · sellers0 · 9
WhoDidSharesTraded
Daniel J. LippisCVP, TAVRsold619at $85.658 Oct 2026filed 8 Oct 2026
Daniel J. LippisCVP, TAVRsold619at $87.5111 Sep 2026filed 11 Sep 2026
Andrew M. DahlSVP, Corporate Controllersold544at $91.0631 Aug 2026filed 31 Aug 2026
Annette BrulsCVP, EMEACLAsold2,644at $89.9828 Aug 2026filed 28 Aug 2026
Wayne MarkowitzCVP, JAPACsold1,240at $91.4726 Aug 2026filed 26 Aug 2026
Daveen ChopraCVP, TMTT, Surgical & IHFMsold1,154at $91.7626 Aug 2026filed 26 Aug 2026
Daveen ChopraCVP, TMTT, Surgical & IHFMsold30,646at $90.9926 Aug 2026filed 26 Aug 2026
Daniel J. LippisCVP, TAVRsold619at $92.0311 Aug 2026filed 11 Aug 2026
Wayne MarkowitzCVP, JAPACsold146.313at $86.0330 Jul 2026filed 30 Jul 2026
Wayne MarkowitzCVP, JAPACsold9,628at $85.0628 Jul 2026filed 28 Jul 2026
Bernard J. ZovighianCEOsold2,920.551at $83.9327 Jul 2026filed 27 Jul 2026
Daniel J. LippisCVP, TAVRsold619at $91.7010 Jul 2026filed 10 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Daniel J. Lippis Company insiderCVP, TAVR · last 8 Oct 20260 · 25
Wayne Markowitz Company insiderCVP, JAPAC · last 14 Sep 20260 · 7
Andrew M. Dahl Company insiderSVP, Corporate Controller · last 13 Sep 20260 · 2
Daveen Chopra Company insiderCVP, TMTT, Surgical & IHFM · last 11 Sep 20260 · 22
Annette Bruls Company insiderCVP, EMEACLA · last 28 Aug 20260 · 1
Bernard J. Zovighian Company insiderCEO · last 27 Jul 20261 · 16
Theodora Mistras Company insiderCVP, Chief Financial Officer · last 9 Jul 20260 · 0
Donald E. Bobo Jr. Company insiderCVP, Strategy/Corp Development · last 27 May 20260 · 157
Donald J. Trump Executive branchWhite House Office · last 11 May 20262 · 1
Scott B. Ullem Company insiderCVP, Chief Financial Officer · last 11 May 20260 · 43
David T. Feinberg Company insiderDirector · last 8 May 20260 · 0
Heisz Leslie Stone Company insiderDirector · last 8 May 20260 · 6

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202578.0%
Operating profit marginFY 2025 · to 31 Dec 202520.8%
Free cash flow marginFY 2025 · to 31 Dec 202522.0%
Return on capital employedFY 2025 · to 31 Dec 202510.6%
Cash conversionFY 2025 · to 31 Dec 2025149%
Debt to equityFY 2025 · to 31 Dec 20250.06×
Interest coverFY 2025 · to 31 Dec 2025-61.97×
Research spendFY 2025 · to 31 Dec 202517.8%
Revenue growthFY 2024 · to 31 Dec 20242.3%
Earnings per share growthFY 2024 · to 31 Dec 2024-87.3%
Share count trendFY 2025 · to 31 Jan 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.9B

Analyst forecasts

No analyst forecasts yet.